Noven Announces Changes to Board of Directors

NOVEN ANNOUNCES CHANGES TO BOARD OF DIRECTORS

Miami, FL, February 12, 2004 -- Noven Pharmaceuticals, Inc. (NASDAQ: NOVN) today announced that Robert G. Savage and Donald A. Denkhaus have been appointed to its board of directors.

Mr. Savage has almost 30 years' experience in the pharmaceutical industry, serving most recently as Group Vice President & President of the General Therapeutics & Inflammation business of Pharmacia Corporation; as Chairman of Johnson & Johnson Pharmaceutical Group; and as President of Ortho-McNeil Pharmaceutical Corp.

Mr. Denkhaus has over 30 years of broad-based business and accounting experience. Most recently he was with Ernst & Young LLP, and previously he worked for Arthur Andersen LLP, serving as an audit partner for 22 years and holding numerous leadership positions.

Noven also announced that current directors Regina E. Herzlinger and Lawrence J. DuBow are not expected to stand for re-election at Noven’s annual shareholders’ meeting in May. Both cited personal reasons for their decision, and both plan to continue to serve as directors until the May meeting.

"We thank Regi and Laurie for many years of service and counsel, and welcome the pharmaceutical and financial experience that Robert and Donald bring to the Noven board," said Robert Strauss, Noven's President, CEO & Chairman.

About Noven
Noven Pharmaceuticals, Inc., headquartered in Miami, Florida, is a leading developer of advanced transdermal drug delivery technologies and prescription transdermal products. Together with Novartis Pharmaceuticals Corporation, Noven owns a profitable women’s health products company called Novogyne Pharmaceuticals. Noven's existing products include advanced estrogen transdermal delivery systems (including Vivelle-Dot^®, licensed to Novogyne, and Estradot^®, licensed to Novartis Pharma AG) and combination estrogen/progestin transdermal delivery systems (including CombiPatch^®, licensed to Novogyne, and Estalis^®, licensed to Novartis Pharma AG). With a range of additional products in development, including MethyPatch^® for ADHD (licensed to Shire Pharmaceuticals Group plc), Noven is committed to becoming the world's premier transdermal drug delivery company. For further information on Noven, including licensing opportunities, visit www.noven.com.

Contact:
Investor & Media Contact
Joseph C. Jones
Vice President – Corporate Affairs
Noven Pharmaceuticals, Inc.
(305) 253-1916

Back